STOK Earnings — Stoke Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
STOK — Stoke Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$30.91
Market Cap$1.9B
P/E—
52W Range$9.47 – $40.22
Next Earnings2026-08-11
About Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
